Pharmaceuticals: Major · attribution context sourced from stored price moves, stored event labels, and peer-relative residuals inside the VWRA constituent company universe.
Review priority 91 · Source rank 0 · Volume 6.5x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -0.84% · Sector +0.86% · Industry +0.85% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +14.00%Review priority 86 · Source rank 0 · Volume 3.6x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +1.50% · Sector +0.85% · Industry +0.67% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +12.67%Review priority 83 · Source rank 0 · Volume 2.9x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +0.77% · Sector +0.08% · Industry +1.12% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +12.32%Review priority 82 · Source rank 0 · Volume 3.3x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -0.21% · Sector +0.33% · Industry +0.61% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +11.01%Review priority 81 · Source rank 0 · Volume 3.1x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +1.62% · Sector -1.72% · Industry -0.41% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +10.89%Review priority 80 · Source rank 0 · Volume 6.0x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +0.15% · Sector +0.46% · Industry +0.52% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +9.02%Review priority 79 · Source rank 0 · Volume 3.6x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +1.32% · Sector -0.72% · Industry -0.53% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -9.16%Review priority 76 · Source rank 60 · Volume 3.0x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +2.06% · Sector +1.21% · Industry +1.16% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +9.02%| Date | Label | Move | Residual after context | Scope | Confidence |
|---|---|---|---|---|---|
| Nov 4, 2020 | Closest peers moved +4.43% with this stock | +13.44% | +9.02% | Peer | 58% |
| Aug 8, 2024 | Broad market moved +2.85% with this stock | +9.48% | +8.40% | Macro | 58% |
| Mar 13, 2020 | Broad market moved +8.36% with this stock | +10.59% | +9.34% | Macro | 58% |
| Mar 20, 2020 | Broad market moved -3.62% with this stock | -8.03% | -8.12% | Macro | 58% |
| Mar 17, 2020 | Broad market moved +5.95% with this stock | +10.68% | +7.32% | Macro | 58% |
| Mar 26, 2020 | Broad market moved +5.78% with this stock | +10.18% | +8.36% | Macro | 58% |
| Oct 1, 2025 | Closest peers moved +3.64% with this stock | +8.18% | +4.54% | Peer | 58% |
| Mar 12, 2020 | Broad market moved -9.15% with this stock | -10.00% | -4.16% | Macro | 58% |
| Aug 7, 2025 | Eli Lilly and Company 10-Q: 10-Q | -14.14% | -0.17% | Direct | 70% |
| Aug 7, 2025 | Eli Lilly and Company 8-K: 8-K | -14.14% | -0.17% | Direct | 70% |